No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH

in European Journal of Endocrinology
View More View Less
  • 1 Unit of Endocrinology, Department of Clinical and Experimental Medicine
  • 2 Department of Nuclear Medicine, University Hospital of Pisa, Pisa, Italy
  • 3 Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Phoenix, Arizona

Correspondence should be addressed to R Elisei; Email: rossella.elisei@med.unipi.it

*(M C Campopiano and D Podestà contributed equally to this work)

Restricted access

Objective:

At present, recombinant TSH cannot be used for the treatment of metastatic differentiated thyroid cancer patients. The aim of this study was to evaluate if the type of TSH stimulation, recombinant or endogenous, had an impact on the outcome of these patients.

Design and methods:

We compared the outcome of two propensity score-matched groups of metastatic patients, stimulated by either only recombinant TSH (n = 43) or only endogenous TSH (n = 34).

Results:

As expected from the matching procedure, the clinical–pathological features and the cumulative 131-I activities administered to the two groups were very similar. After 4 years of follow-up, 4% of patients were cured, 3% had biochemical disease and 93% had structural disease. However, 91% of patients obtained a clinical benefit from this therapy in terms of stabilization of the disease or complete remission or partial response. When considering the two groups separately, we did not find any difference in their outcome. When considering the response to 131-I therapy of the single type of metastases, 8% of lymph node metastases and 8% of lung metastases disappeared but none of the bone metastases. The response to 131-I therapy of the single type of metastases was similar when we looked at the two groups separately.

Conclusions:

This study shows (i) an overall clinical benefit of the 131-I therapy, since the majority of patients remained affected but with a stable disease, and (ii) that the preparation with either recombinant or endogenous TSH has no impact on the 131-I therapy efficacy and the outcome of our two groups of patients.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 322 322 319
Full Text Views 30 30 30
PDF Downloads 23 23 23
  • 1

    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM & Schlumberger M 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 26 1133. (https://doi.org/10.1089/thy.2015.0020)

    • Search Google Scholar
    • Export Citation
  • 2

    Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C & Molinaro E Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 2006 91 926932. (https://doi.org/10.1210/jc.2005-1651)

    • Search Google Scholar
    • Export Citation
  • 3

    Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. Journal of Nuclear Medicine 2002 43 14821488.

    • Search Google Scholar
    • Export Citation
  • 4

    Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001 11 865869. (https://doi.org/10.1089/105072501316973127)

    • Search Google Scholar
    • Export Citation
  • 5

    Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nuclear Medicine Communications 2006 27 627632. (https://doi.org/10.1097/00006231-200608000-00005)

    • Search Google Scholar
    • Export Citation
  • 6

    Badihian S, Jalalpour P, Mirdamadi M, Moslehi M. Quality of life, anxiety and depression in patients with differentiated thyroid cancer under short term hypothyroidism induced by levothyroxine withdrawal. Klinicka Onkologie 29 439444. (https://doi.org/10.14735/amko2016439)

    • Search Google Scholar
    • Export Citation
  • 7

    Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. European Journal of Endocrinology 2007 156 1319. (https://doi.org/10.1530/eje.1.02310)

    • Search Google Scholar
    • Export Citation
  • 8

    Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613619. (https://doi.org/10.1089/thy.1997.7.613)

    • Search Google Scholar
    • Export Citation
  • 9

    An JH, Song KH, Kim DL, Kim SK. Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer. Journal of International Medical Research 2017 45 3850. (https://doi.org/10.1177/0300060516664242)

    • Search Google Scholar
    • Export Citation
  • 10

    Wang TS, Cheung K, Mehta P, Roman SA, Walker HD, Sosa JA. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. Journal of Clinical Endocrinology and Metabolism 2010 95 16721680. (https://doi.org/10.1210/jc.2009-1803)

    • Search Google Scholar
    • Export Citation
  • 11

    Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to Recombinant Thyrotropin Administration. Thyroid 2005 15 11471155. (https://doi.org/10.1089/thy.2005.15.1147)

    • Search Google Scholar
    • Export Citation
  • 12

    Borger J, Remy H, Chevalier J, Ricard M, Allyn M, De Pourvouville G. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 14571463. (https://doi.org/10.1007/s00259-008-0754-9)

    • Search Google Scholar
    • Export Citation
  • 13

    Guo Y, Zhang Y, Chen Z, Xin Z. Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer. Experimental and Therapeutic Medicine 2015 9 18471850. (https://doi.org/10.3892/etm.2015.2330)

    • Search Google Scholar
    • Export Citation
  • 14

    Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010 20 173179. (https://doi.org/10.1089/thy.2009.0187)

    • Search Google Scholar
    • Export Citation
  • 15

    Testori O, Bagnasco M, Banti E, Bombardieri E, Dottorini ME, Fugazzola L, Maffioli L, Perotti G, Rubello D, Seregni E. Radiometabolic therapy for metastatic thyroid carcinoma: overview of the literature and rational bases for the use of recombinant human TSH. Minerva Medica 2012 103 209218.

    • Search Google Scholar
    • Export Citation
  • 16

    Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A & Pacini F American Thyroid Association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid 2017 27 481483. (https://doi.org/10.1089/thy.2016.0628)

    • Search Google Scholar
    • Export Citation
  • 17

    Robbins RJ, Driedger A, Magner J & U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006 16 11211130. (https://doi.org/10.1089/thy.2006.16.1121)

    • Search Google Scholar
    • Export Citation
  • 18

    Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 2005 12 4964. (https://doi.org/10.1677/erc.1.00830)

    • Search Google Scholar
    • Export Citation
  • 19

    Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. Journal of Clinical Endocrinology and Metabolism 2011 96 21052111. (https://doi.org/10.1210/jc.2011-0305)

    • Search Google Scholar
    • Export Citation
  • 20

    Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 2012 22 310317. (https://doi.org/10.1089/thy.2011.0235)

    • Search Google Scholar
    • Export Citation
  • 21

    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S & Mooney M New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 228247. (https://doi.org/10.1016/j.ejca.2008.10.026)

    • Search Google Scholar
    • Export Citation
  • 22

    AJCC – American Joint Committee on Cancer. (available at: https://cancerstaging.org/Pages/default.aspx). Accessed on 30 January 2020.

  • 23

    Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, Dudczak R. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clinical Endocrinology 2006 65 519523. (https://doi.org/10.1111/j.1365-2265.2006.02626.x)

    • Search Google Scholar
    • Export Citation
  • 24

    Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD & De Vathaire F Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 28922899. (https://doi.org/10.1210/jc.2005-2838).

    • Search Google Scholar
    • Export Citation